Compounding is the process of preparing personalized medications by a licensed pharmacist
Patterson BK, Guevara-Coto J, Yogendra R, Francisco E, Long E, Pise A, et al
Medications highlighted in the graphic include: Oral Wegovy - GLP-1 receptor agonist - ~13 to 17% estimated weight loss Wegovy 7.2 mg - Higher-dose injectable GLP-1 - ~20 to 21% estimated weight loss Orforglipron - Oral non-peptide GLP-1 agonist - ~11 to 15% estimated weight loss CagriSema - Amylin analog + GLP-1 agonist - ~20 to 23% estimated weight loss Retatrutide - Triple agonist (GIP, GLP-1, glucagon) - up to ~28 to 29% estimated weight loss Survodutide - Dual agonist (GLP-1, glucagon) - ~15 to 19% estimated weight loss MariTide - GIP antagonist + GLP-1 antibody-drug conjugate - ~18 to 20% estimated weight loss A few important notes for context: The percentages shown are trial-based estimates and vary by dose, duration, and analysis method Timelines reflect best estimates, not guarantees Real-world outcomes will depend on access, tolerability, and individualized care That said, the direction is clear

Clinical and real-world reports suggest that tiredness occurs in roughly 5-7% of people taking tirzepatide, making it a recognized but not universal side effect
Proximity narrows you to one region, and if you stop rotating inside it you will build a nodule within a couple of weeks and absorption will get unpredictable right where you wanted it consistent
The most important factor is proper monitoring of thyroid levels and medication timing to avoid absorption issues